Navigation Links
Tested a drug that strengthens the analgesic effect of opioids without increasing constipation
Date:3/31/2014

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine.

This important scientific breakthrough has been published in The Journal of Pharmacology and Experimental Therapeutics, and has been chosen as its outstanding article in the month of January. So far, the University of Granada researchers have published the results from testing this molecule on mice.

Opium derivates have been used since ancient times to treat pain. Currently, these and similar products (opioids) are the drugs used to treat various types of intense pain, such as post-operatory pain, cancer pain or internal-organ pain. The prolonged use of opioids causes strong constipation, which is a substantial drawback to their administration, since it substantially diminishes patient well-being.

The recently-published article proves that S1RA, a drug that blocks the sigma-1 receptor, manages to multiply solely the beneficial effect of the opioids; that is, their pain-killing properties.

The sigma-1 receptor is a very small protein that acts as a neuro-modulator, physically linking to other proteins (among which are the opioid receptors) and modifying their function.

As Enrique Cobos del Moral, one of the authors and a researcher at the University of Granada Institute of Neuroscience, explains, opioids are basically "centrally-acting" drugs; that is, they act directly upon the brain and the spinal medula. However, when opioids are associated with sigma-1 receptor blockers, their pain-killing effects are brought about by acting upon other areas; specifically, on the peripheral nervous system. From this, it is deduced that the sigma-1 receptor is a biological brake that prevents peripheral opioid analgesia, and that this brake can be eliminated by pharmacological treatment so as to increase the pain-killing power of opioids.

This scientific breakthrough is of huge importance for the well-being of patients suffering from pain, since, in the short term, it will allow the development of more efficient painkillers with fewer side-effects.

Esteve is working on the development of this medication, which is currently in Clinical Phase II


'/>"/>

Contact: Enrique J. Cobos del Moral
ejcobos@ugr.es
34-958-243-538
University of Granada
Source:Eurekalert  

Related medicine news :

1. Study questions anti-cancer mechanisms of drug tested in clinical trials
2. Data show drug being tested to reduce cardiovascular events increased risk of heart attack
3. Kirkman® Adds New Comprehensive Antioxidant to Ultra Tested® Product Line: Antioxidant/Cell Protect – Hypoallergenic
4. Brain Research Labs Brain Health And Performance News: Pioneer in the Field of Cognitive Performance and Health Succeeds with Clinically-Tested Natural Solutions
5. Fully Dissolvable, Temporary Stent for Opening Heart Artery Blockages Now Being Tested at The Mount Sinai Medical Center
6. Magellan Echo to Be Tested by Heart Rate Watch Company
7. Baron and Budd Supports the Newest Drug Being Tested for Mesothelioma Treatment
8. This Tested and Proven Ingredient Should be in Every Adults Daily Regime for Younger Skin, Says Sublime Beauty
9. SafeToSleep Baby Monitor Wins Parent Tested Parent Approved (PTPA) Award
10. Through New Innovative Measures, Highly Pathogenic Microbes Will Now Be Tested Clinically, Strengthening The Front Line In The Fight Against Food-Borne Illness
11. Handheld device for detecting counterfeit and substandard medicines tested by PQM
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tested a drug that strengthens the analgesic effect of opioids without increasing constipation
(Date:6/20/2017)... ... June 20, 2017 , ... In his newly appointed role ... May, Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s ... (WNB), and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, ...
(Date:6/20/2017)... West Hempstead, NY (PRWEB) , ... June 20, ... ... most experienced in the security systems industry has been selected as the partner ... , Amtrak is a passenger railroad service that provides medium- and long-distance intercity ...
(Date:6/20/2017)... ... 2017 , ... John D'Eri, CEO of Rising Tide Car Wash , ... during the Autism Society of America 's 49th annual conference to be ... Foundation (DJFF) was founded in 2002 as the nation's first autism organization focused ...
(Date:6/20/2017)... ... June 20, 2017 , ... MEDI+SIGN, ... like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. ... and expertise in healthcare will provide invaluable direction for the company,” says Andrew ...
(Date:6/20/2017)... ... , ... The law firm of Momkus McCluskey Roberts LLC congratulates ... DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the leadership role ... Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology: